Data of the third phase of clinical trials of Bharat Biotech's Covaxin are out. The efficacy figures are highly encouraging.

It has been discovered that the vaccine has got a 77.8% efficacy against symptomatic infection of coronavirus. And it is 93.4% effective against severe symptomatic Covid-19. Also, Covaxin has 65.2% efficacy against the Delta variant.

In a statement, Bharat Biotech said that the final analysis for Covaxin efficacy as part of phase 3 clinical trials was concluded after an evaluation of 130 confirmed cases. "Covaxin's efficacy demonstrated at 77.8% against symptomatic COVID19 patients," the company iterated.

It was concluded after the largest efficacy trial in India at 25 trial sites. People from 18 to 98 years of age were studied. "Covaxin is well tolerated with minimal adverse events post-immunization," the company said.

After Covishield, Covaxin is the highest in use in India. Millions of people have already received the vaccine. The Phase 3 data instills confidence in those who have received it and who are going to receive it.